Higher Long-Term Mortality in Patients with Non-ST-Elevation Myocardial Infarction than ST-Elevation Myocardial Infarction after Discharge

Han, Xiongyi; Bai, Liyan; Jeong, Myung Ho; Ahn, Joon Ho; Hyun, Dae Young; Cho, Kyung Hoon; Kim, Min Chul; Sim, Doo Sun; Hong, Young Joon; Kim, Ju Han; Ahn, Youngkeun; Investigators, Other Kamir-Nih Registry

doi:10.3349/ymj.2021.62.5.400

Cited by 10 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were more patients with STEMI in the smoker group than in the non-smoker group. According to a clinical study based on the KAMIR-NIH registry (34), patients with STEMI tended to have more favorable outcomes than did those with NSTEMI. Smokers had lower TIT, S2DT, and D2BT than non-smokers, indicating that PCI was performed relatively quicker in the smoking group.…”

Section: Discussionmentioning

confidence: 99%

Association between baseline smoking status and clinical outcomes following myocardial infarction

Kim

Cho

et al. 2022

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

BackgroundWhether the effect of smoking on clinical outcomes following an acute myocardial infarction (AMI) is beneficial or detrimental remains inconclusive. We invesetigated the effect of smoking on the clinical outcomes in patients following an AMI.MethodsAmong 13,104 patients between November 2011 and June 2015 from a nationwide Korean AMI registry, a total of 10,193 participants were extracted then classified into two groups according to their smoking habit: (1) smoking group (n = 6,261) and (2) non-smoking group (n = 3,932). The participants who smoked were further subclassified according to their smoking intensity quantified by pack years (PYs): (1) <20 PYs (n = 1,695); (2) 20–40 PYs (n = 3,018); and (3) ≥40 PYs (n = 2,048). Each group was compared to each other according to treatment outcomes. The primary outcome was the incidence of major adverse cardiac and cerebrovascular events (MACCEs), which is a composite of all-cause mortality, non-fatal MI (NFMI), any revascularization, cerebrovascular accident, rehospitalization, and stent thrombosis. Secondary outcomes included the individual components of MACCEs. The Cox proportional hazard regression method was used to evaluate associations between baseline smoking and clinical outcomes following an AMI. Two propensity score weighting methods were performed to adjust for confounders, including propensity score matching and inverse probability of treatment weighting.ResultsWhile the incidence of all clinical outcomes, except for stent thrombosis, was lower in the smoking group than in the non-smoking group in the unadjusted data, the covariates-adjusted data showed statistical attenuation of these differences but a higher all-cause mortality in the smoking group. For smokers, the incidence of MACCEs, all-cause mortality, cardiac and non-cardiac death, and rehospitalization was significantly different between the groups, with the highest rates of MACCE, all-cause mortality, non-cardiac death, and rehospitalization in the group with the highest smoking intensity. These differences were statistically attenuated in the covariates-adjusted data, except for MACCEs, all-cause mortality, and non-cardiac death, which had the highest incidence in the group with ≥40 PYs.ConclusionSmoking had no beneficial effect on the clinical outcomes following an AMI. Moreover, for those who smoked, clinical outcomes tended to deteriorate as smoking intensity increased.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between baseline smoking status and clinical outcomes following myocardial infarction

Kim

Cho

et al. 2022

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…According to the current estimates of the Global Burden Disease Study (GBD) 2019, cardiovascular diseases (CVDs), with more than 390 million disability‐adjusted life years, were the primary cause of disability worldwide 1 . Despite the public perception that CVD mortality has decreased due to the development of therapeutic equipment, it has increased dramatically from 12.1 to 18.6 million since 1990 1,2 . Furthermore, acute myocardial infarction (AMI) is the leading cause of global CVDs‐related deaths 3 .…”

Section: Introductionmentioning

confidence: 99%

“… 1 Despite the public perception that CVD mortality has decreased due to the development of therapeutic equipment, it has increased dramatically from 12.1 to 18.6 million since 1990. 1 , 2 Furthermore, acute myocardial infarction (AMI) is the leading cause of global CVDs‐related deaths. 3 Hence, several studies reevaluated the predisposing factors that lead AMI to fatal consequences.…”

Section: Introductionmentioning

confidence: 99%

Risk assessment for mortality in patients with ST‐elevation myocardial infarction undergoing primary percutaneous coronary intervention: A retrospective cohort study

Oraii,

Shafeghat,

Ashraf

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

Background and AimsPrimary percutaneous coronary intervention (PCI) is the treatment of choice in ST‐elevation myocardial infarction (STEMI) patients. This study aims to evaluate predictors of in‐hospital and long‐term mortality among patients with STEMI undergoing primary PCI.MethodsIn this registry‐based study, we retrospectively analyzed patients with STEMI undergoing primary PCI enrolled in the primary angioplasty registry of Sina Hospital. Independent predictors of in‐hospital and long‐term mortality were determined using multivariate logistic regression and Cox regression analyses, respectively.ResultsA total of 1123 consecutive patients with STEMI were entered into the study. The mean age was 59.37 ± 12.15 years old, and women constituted 17.1% of the study population. The in‐hospital mortality rate was 5.0%. Multivariate analyses revealed that older age (odds ratio [OR]: 1.06, 95% confidence interval [CI]: 1.02–1.10), lower ejection fraction (OR: 0.97, 95% CI: 0.92–0.99), lower mean arterial pressure (OR: 0.95, 95% CI: 0.93–0.98), and higher white blood cells (OR: 1.17, 95% CI: 1.06–1.29) as independent risk predictors for in‐hospital mortality. Also, 875 patients were followed for a median time of 21.8 months. Multivariate Cox regression demonstrated older age (hazard ratio [HR] = 1.04, 95% CI: 1.02–1.06), lower mean arterial pressure (HR = 0.98, 95% CI: 0.97–1.00), and higher blood urea (HR = 1.01, 95% CI: 1.00–1.02) as independent predictors of long‐term mortality.ConclusionWe found that older age and lower mean arterial pressure were significantly associated with the increased risk of in‐hospital and long‐term mortality in STEMI patients undergoing primary PCI. Our results indicate a necessity for more precise care and monitoring during hospitalization for such high‐risk patients.

show abstract

“…Myocardial infarction(MI) is a common cause of death and is associated with high mortality rates [ 17 ]. Despite advancements in diagnosis and treatment, the incidence of myocardial infarction (MI) has gradually increased [ 18 ]. Therefore, it is imperative to explore novel predictors of MI.…”

Section: Introductionmentioning

confidence: 99%

The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis

Lv,

Zhao

2024

Annals of Medicine

View full text Add to dashboard Cite

Objective While studies have documented how metabolic dysfunction-associated steatotic liver disease (MASLD) can contribute to cardiovascular disease (CVD), whether MASLD is associated with myocardial infarction (MI) remains debateable. Herein, we systematically reviewed published articles and performed a meta-analysis to determine the relationship between MASLD and MI risk. Methods PubMed, MEDLINE, Embase, Web of Science, CNKI, CBM, VIP, and WanFang databases were searched, and the DerSimonian Laird method was used to obtain hazard ratios (HRs) for binary variables to assess the correlation between MASLD and MI risk. Subgroup analyses for the study region, MASLD diagnosis, quality score, study design, and follow-up time were conducted simultaneously for the selected studies retrieved from the time of database establishment to March 2022. All study procedures were independently conducted by two investigators. Results The final analysis included seven articles, including eight prospective and two retrospective cohort studies. The MI risk was higher among MASLD patients than among non-MASLD patients (HR = 1.26; 95% CI: 1.08-1.47, p = 0.003). The results of the subgroup analysis of the study region revealed an association of MASLD with MI risk among Americans and Asians, but not in Europeans. Subgroup analyses of MASLD diagnosis showed that ultrasonography and other (fatty liver index[FLI] and computed tomography [CT)]) diagnostic methods, but not international classification of disease (ICD), increased the risk of MI. Subgroup analysis of the study design demonstrated a stronger relationship between MASLD and MI in retrospective studies but not in prospective studies. Subgroup analysis based on the follow-up duration revealed the association of MASLD with MI risk in cases with < 3 years of follow-up but not with ≥3 years of follow-up. Conclusion MASLD increases the risk of MI, independent of traditional risk factors.

show abstract

Higher Long-Term Mortality in Patients with Non-ST-Elevation Myocardial Infarction than ST-Elevation Myocardial Infarction after Discharge

Cited by 10 publications

References 32 publications

Association between baseline smoking status and clinical outcomes following myocardial infarction

Association between baseline smoking status and clinical outcomes following myocardial infarction

Risk assessment for mortality in patients with ST‐elevation myocardial infarction undergoing primary percutaneous coronary intervention: A retrospective cohort study

The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis

Contact Info

Product

Resources

About